Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEton Pharmaceuticals Inc

Eton Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
59.568 USD 3.11 ( 5.50%)
Last update at 2026-11-09T15:41:00Z
VOLUME
192401
Market Cap
1570.07M
P/E
148.46

Momentum Score

…

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
57.02
Low
59.64
High
52 Week Price Range
14.27
Low
66.37
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eton Pharmaceuticals is a specialty pharmaceutical company that develops, acquires and commercializes branded and generic prescription medicines for niche therapeutic markets. Long-term growth drivers include product launches, in‑licensing and pipeline progression toward approvals, plus scaling commercial and manufacturing capabilities; these factors may support recurring specialty revenues and appeal to investors seeking small‑cap exposure to niche drug franchises.

Key risks include regulatory setbacks, reliance on a small number of products, competition and reimbursement pressure, and execution risks in manufacturing and commercialization; investors should monitor clinical and commercial outcomes.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
56.46
Dividend Yield
-
Revenue TTM
105.59M
Revenue Per Share
3.88
Gross Profit TTM
64.85M
Debt / Equity
1.19
ROE
35.97%
Net Debt
5.08M
ROCE
0.42%
Diluted EPS TTM
0.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -4.56M -3.81M -0.69M -9.02M -1.96M
Net income -4.60M -3.82M -0.94M -9.78M -2.96M
Selling general administrative 35.82M 22.75M 18.93M 18.58M 14.47M
Selling and marketing expenses - - 0.07M - -
Gross profit 42.74M 23.41M 21.06M 14.32M 19.21M
Reconciled depreciation 4.04M 1.15M 0.90M 1.77M 0.46M
Ebit 0.22M -1.80M -0.69M -8.26M -1.50M
Ebitda 4.27M -0.66M 0.21M -6.49M -1.03M
Depreciation and amortization 4.04M 1.15M 0.90M 1.77M 0.46M
Non operating income net other - - - -0.76M -
Operating income 0.07M -2.60M -1.19M -8.26M -1.50M
Other operating expenses 79.88M 41.61M 32.83M 29.51M 23.33M
Interest expense 4.78M 2.00M 1.06M 0.76M 1.01M
Tax provision 0.04M 0.01M 0.25M 0.00M 0.00M
Net interest income -3.71M -1.21M 0.50M -0.76M -1.01M
Income tax expense 0.04M 0.01M 0.25M 0.76M 1.01M
Total revenue 79.95M 39.01M 31.64M 21.25M 21.83M
Total operating expenses 42.67M 26.01M 22.25M 22.58M 20.70M
Cost of revenue 37.21M 15.60M 10.58M 6.93M 2.62M
Total other income expense net -4.63M -1.21M 0.50M -0.76M -0.46M
Net income from continuing ops -4.60M -3.82M -0.94M -9.02M -1.96M
Net income applicable to common shares - - - -9.02M -1.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 92.11M 76.12M 31.74M 25.03M 27.46M
Intangible assets 30.88M 34.88M 4.74M 4.75M 3.62M
Other current assets 7.46M 5.49M 1.13M 1.29M 3.18M
Total liab 65.96M 51.70M 16.26M 11.95M 9.84M
Total stockholder equity 26.15M 24.43M 15.48M 13.08M 17.63M
Other current liab 18.73M 15.70M 8.96M 3.66M 1.37M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -112.49M -107.89M -104.07M -103.13M -94.11M
Other assets - - - 0.01M 0.02M
Cash 25.94M 14.94M 21.39M 16.30M 14.41M
Total current liabilities 38.49M 19.95M 16.24M 6.46M 4.56M
Net debt 5.08M 15.06M -15.93M -9.78M -7.71M
Short term debt 8.79M 0.08M 5.43M 1.03M 1.42M
Short long term debt 8.79M - 5.38M 1.03M 1.42M
Short long term debt total 31.02M 29.99M 5.46M 6.52M 6.70M
Other stockholder equity 138.62M 132.29M 119.52M 116.19M 111.72M
Property plant equipment - - - 0.07M 0.22M
Total current assets 60.58M 41.02M 26.84M 20.00M 23.60M
Net tangible assets - - - 8.32M 14.01M
Net receivables 11.76M 5.36M 3.41M 1.85M 5.47M
Long term debt 21.77M 29.81M - 5.38M 5.26M
Inventory 15.42M 15.23M 0.91M 0.56M 0.55M
Accounts payable 10.98M 4.17M 1.85M 1.77M 1.77M
Common stock total equity - - - 0.03M -
Retained earnings total equity - - - -103.13M -
Non currrent assets other 0.02M 0.01M 0.01M 0.01M 0.02M
Non current assets total 31.53M 35.10M 4.90M 5.03M 3.86M
Capital lease obligations 0.46M 0.11M 0.02M 0.11M 0.01M
Long term debt total - - - 5.38M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -40.01M -0.78M -2.79M -2.56M
Change to liabilities - - - 2.21M -0.57M
Total cashflows from investing activities -0.33M -40.01M -0.78M -2.79M -2.56M
Net borrowings 0.00M 24.15M -1.16M -0.39M -0.15M
Total cash from financing activities 0.81M 32.59M -0.96M -0.13M 0.39M
Change to operating activities - - - 4.12M -0.91M
Net income -4.60M -3.82M -0.94M -9.02M -1.96M
Change in cash 11.01M -6.45M 5.08M 1.90M -6.89M
Begin period cash flow 14.94M 21.39M 16.30M 14.41M 21.30M
End period cash flow 25.94M 14.94M 21.39M 16.30M 14.41M
Total cash from operating activities 10.52M 0.97M 6.82M 4.82M -4.72M
Issuance of capital stock 0.00M 7.00M 0.00M 0.00M 0.00M
Depreciation 4.04M 1.15M 0.90M 1.77M 0.46M
Other cashflows from investing activities - -9.99M - -2.75M -
Change to inventory -5.88M -1.31M -0.35M -0.01M 0.69M
Change to account receivables -6.40M -3.12M -1.56M 3.62M -5.42M
Sale purchase of stock - - - 0.25M -
Other cashflows from financing activities 0.22M 0.25M 0.20M 0.25M 0.54M
Change to netincome - - - 4.22M 2.83M
Capital expenditures 0.33M 0.03M 0.78M 2.79M 3.26M
Change receivables - - - 3.62M -
Cash flows other operating - - - 1.90M -
Cash and cash equivalents changes - - - 1.90M -
Change in working capital -0.86M -0.70M 3.53M 7.72M -6.21M
Stock based compensation 5.51M 3.17M 3.14M 4.22M 3.38M
Other non cash items 6.43M 1.18M 0.18M 0.13M 0.15M
Free cash flow 10.19M 0.94M 6.04M 2.03M -7.98M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ETON
Eton Pharmaceuticals Inc		 3.11
5.50%		 59.57 148.46 24.75 14.87 35.35 15.62 79.09
MKKGY
Merck KGaA ADR		 0.49
1.48%		 33.66 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.05
0.24%		 20.97 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.50
1.19%		 42.35 - 10.66 0.01 1.16 2.94 23.11

Profile*

Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278

847 787 7361

https://www.etonpharma.com

44

Name Title Year Born
Mr. Sean E. Brynjelsen Pres, CEO & Director 1972
Mr. James R. Gruber CPA CFO, Treasurer & Sec. 1972
Mr. David Krempa Sr. VP of Bus. Devel. & Investor Relations NA
Ms. Ingrid Hoos Sr. VP of Regulatory Affairs NA
Mr. Kevin Guthrie Exec. VP of Commercial Operations NA
Mr. Scott Grossenbach VP of Sales & Marketing NA
Mr. Sean E. Brynjelsen President, CEO & Director 1972
Mr. James R. Gruber CPA CFO, Treasurer & Secretary 1972
Mr. David C. Krempa Chief Business Officer 1989
Ms. Ingrid Hoos Senior Vice President of Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…